Exagen receives conditional approval for new lupus and RA biomarker assays in New York.

From Nasdaq: 2025-01-12 13:04:51

Exagen Inc. has received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus and rheumatoid arthritis biomarker assays. The company plans to launch these assays in January 2025, aiming to improve the clinical utility of its AVISE CTD platform and provide clinicians with better tools for diagnosing autoimmune diseases. In the fourth quarter, Exagen projects a net loss between $3.4 million to $4.4 million and revenue of $13.3 million to $13.8 million.



Read more at Nasdaq: Exagen Gets Conditional Approval For New Lupus And RA Biomarker Assays In New York